Accumulating evidence suggests that many conventional cancer treatments, including DNA‐damaging chemotherapy and radiotherapy, elicit additional therapeutic benefits by iatrogenic activation of the STING pathway.[8] These insights have fueled intense interest in developing STING agonists as a promising strategy for cancer immunotherapy. Here, STING1 is linked to cancer.